CLOs on the Move

StoryArc Media

www.storyarc.media.com

 
At StoryArc Media, we create fun, engaging, interactive experiences that light up kids` faces and brains. Every day and all around the world, kids enjoy our online games, mobile apps, books, and more, including Poptropica, Funbrain, Galactic Hot Dogs, and Mystery of the Map. Parents and educators think we`re pretty cool, too, because while StoryArc Media creations are oodles of fun, they also educate and reward players. And our online games and apps for kids under 13 carry the KidSAFE seal, so adults can be assured that children are exploring in a safe environment.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Bluecube Technology Solutions

Bluecube is an IT service provider that offers managed IT services, cyber security, strategic guidance and consultancy, and IT service desk provision. They aim to make peoples lives easier, more connected, organised, and secure.

TicketSmarter

Official Ticket Resale Partner of Rose Bowl Stadium. Official secondary ticketing partner of ESPN Events and title partner of the TicketSmarter Birmingham Bowl.

SpaceIQ

SpaceIQ is a Silicon Valley technology company founded by seasoned business and technology leaders to help innovate and inspire the Facility Management software industry.

ScaleNorth

ScaleNorth is a company that provides NetSuite implementations, consulting, integrations, outsourced accounting and more.

Immunome

Immunome is a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system. Our unique and powerful immunotherapy discovery engine leverages “most highly educated” immune systems from patients who have already learned how to fight off their disease. This proprietary technology platform enables the simultaneous discovery of novel antigens and the patient-derived, native antibodies that target those antigens. We then employ a battery of high-content screening technologies to identify specific and high-affinity antibodies that offer significant therapeutic potential to change the way we treat cancer.